Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | December 05, 2019 | December 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,360 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 272 · Balance 78,360 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 83 |
Reported balance
Holding disclosure · report date 2026-07-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 83 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
MYRIAD GENETICS INC
Report date December 05, 2019 · Filed December 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,040 |
Reported balance
After 2019-12-05 transaction · row 1
1 source rowRow 1 · 2019-12-05 · Grant · Acquired 11,687 · Balance 76,040 F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 2,050 |
Reported balance
Holding disclosure · report date 2019-12-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,050 |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 16, 2026 20:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 272 | $82.62 | $22,472.64 |
DisclosureSEC source: 0001061983-26-000080 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,360 F1 · kind: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 4,301 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0001061983-26-000059 · form4.xml · derivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,301 Underlying: Common Stock · 4,301 shares Expires 2036-05-26 Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000059 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,088 Read SEC document |
| May 05, 2026 Filed May 5, 2026 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001061983-26-000048 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 5, 2026 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 20,000 | $75.97 | $1,519,400.00 |
DisclosureSEC source: 0001061983-26-000048 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,237 Read SEC document |
| May 05, 2026 Filed May 5, 2026 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 20,000 | $7.61 | $152,200.00 |
DisclosureSEC source: 0001061983-26-000048 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 325 | $65.37 | $21,245.25 |
DisclosureSEC source: 0001061983-26-000039 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,237 F1 · kind: Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 334 | $63.44 | $21,188.96 |
DisclosureSEC source: 0001061983-26-000005 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,912 F1 · kind: Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors. Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000042 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 8,750 | $63.90 | $559,125.00 |
DisclosureSEC source: 0001061983-25-000042 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,578 Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 8,750 | $10.00 | $87,500.00 |
DisclosureSEC source: 0001061983-25-000042 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 338 | $62.80 | $21,226.40 |
DisclosureSEC source: 0001061983-25-000012 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,578 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 21:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 559 | $38.01 | $21,247.59 |
DisclosureSEC source: 0001127602-25-019293 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,240 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,880 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014364 · form4.xml · derivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2035-05-13 F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014364 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,681 F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001127602-25-012129 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,190 | $38.66 | $123,325.40 |
DisclosureSEC source: 0001127602-25-012129 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,348 Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 20,000 | $6.21 | $124,200.00 |
DisclosureSEC source: 0001127602-25-012129 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 551 | $38.56 | $21,246.56 |
DisclosureSEC source: 0001127602-25-012117 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,348 F1 · kind: Shares acquired pursuant to Director Stock in lieu of Cash Retainer Program. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 434 | $48.93 | $21,235.62 |
DisclosureSEC source: 0001127602-25-000771 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,987 F1 · kind: Director Stock in Lieu of Cash Retainer Program Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,092 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001127602-24-029248 · form4.xml · derivative · entry 6 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,092 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 1,780 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001127602-24-029248 · form4.xml · derivative · entry 5 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,092 Underlying: Common Stock · 1,780 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,092 | $7.37 | $74,378.04 |
DisclosureSEC source: 0001127602-24-029248 · form4.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,780 | $50.42 | $89,747.60 |
DisclosureSEC source: 0001127602-24-029248 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,461 Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,780 | $7.37 | $13,118.60 |
DisclosureSEC source: 0001127602-24-029248 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 403 | $52.60 | $21,197.80 |
DisclosureSEC source: 0001127602-24-025196 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,461 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document |
| July 01, 2024 Filed Jul 4, 2024 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020146 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,058 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document |
| May 15, 2024 Filed May 16, 2024 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 3,636 | $0.00 Strike: $60.50 | $0.00 |
DisclosureSEC source: 0001127602-24-015722 · form4.xml · derivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,636 Underlying: Common Stock · 3,636 shares Expires 2034-05-15 Read SEC document |
| May 15, 2024 Filed May 16, 2024 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015722 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,670 Read SEC document |
| April 25, 2024 Filed Apr 25, 2024 22:54 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,562 | $64.54 | $681,671.48 |
DisclosureSEC source: 0001127602-24-013411 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,070 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001127602-24-004994 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $76.48 | $382,400.00 |
DisclosureSEC source: 0001127602-24-004994 · form4.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,632 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $4.44 | $22,200.00 |
DisclosureSEC source: 0001127602-24-004994 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. Read SEC document |
| January 12, 2024 Filed Jan 12, 2024 22:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001127602-24-001286 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. Read SEC document |
| January 12, 2024 Filed Jan 12, 2024 22:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $85.14 | $425,700.00 |
DisclosureSEC source: 0001127602-24-001286 · form4.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,632 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. Read SEC document |
| January 12, 2024 Filed Jan 12, 2024 22:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $4.44 | $22,200.00 |
DisclosureSEC source: 0001127602-24-001286 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 252 | $84.12 | $21,198.24 |
DisclosureSEC source: 0001127602-24-000425 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,632 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $84.12, representing the closing stock price of the Issuer's common stock on January 2, 2024. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 13,020 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001127602-23-030007 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,020 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. F2 · kind: Sell-to-cover transaction. Dr. Henderson acquired a net 10,562 shares of common stock, which he continues to hold. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,458 | $36.34 | $89,323.72 |
DisclosureSEC source: 0001127602-23-030007 · form4.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,380 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. F2 · kind: Sell-to-cover transaction. Dr. Henderson acquired a net 10,562 shares of common stock, which he continues to hold. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 13,020 | $6.72 | $87,494.40 |
DisclosureSEC source: 0001127602-23-030007 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 18, 2023. F2 · kind: Sell-to-cover transaction. Dr. Henderson acquired a net 10,562 shares of common stock, which he continues to hold. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 762 | $27.88 | $21,244.56 |
DisclosureSEC source: 0001127602-23-025181 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,818 F1 · shares: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $27.88, representing the closing stock price of the Issuer's common stock on October 2, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 636 | $33.36 | $21,216.96 |
DisclosureSEC source: 0001127602-23-020048 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,056 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $33.36, representing the closing stock price of the Issuer's common stock on July 3, 2023. Read SEC document |
| May 15, 2023 Filed May 15, 2023 20:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 4,166 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001127602-23-015541 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2022. Read SEC document |
| May 15, 2023 Filed May 15, 2023 20:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,166 | $37.77 | $157,349.82 |
DisclosureSEC source: 0001127602-23-015541 · form4.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,420 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2022. Read SEC document |
| May 15, 2023 Filed May 15, 2023 20:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,166 | $6.78 | $28,245.48 |
DisclosureSEC source: 0001127602-23-015541 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2022. Read SEC document |
| May 10, 2023 Filed May 18, 2023 20:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001127602-23-016169 · form4.xml · derivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-10 F2 · kind: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024. Read SEC document |
| May 10, 2023 Filed May 18, 2023 20:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016169 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,420 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 530 | $37.71 | $19,986.30 |
DisclosureSEC source: 0001127602-23-012552 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,420 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $37.71, representing the closing stock price of the Issuer's common stock on April 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 450 | $44.35 | $19,957.50 |
DisclosureSEC source: 0001127602-23-000692 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,890 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $44.35, representing the closing stock price of the Issuer's common stock on January 3, 2023. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 391 | $51.11 | $19,984.01 |
DisclosureSEC source: 0001127602-22-023698 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,440 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of the Issuer's common stock on October 3, 2011. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.